SCHEMBL3496923

SCHEMBL3496923

CC(C)(C)OC(=O)c1cc(Br)cc(-c2cccnc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.48
KMO O15229 1/20 0.46
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 2/20 0.44
CYP19A1 P11511 1/20 0.44
SLC2A1 P11166 1/20 0.42
MKNK1 Q9BUB5 5/20 0.41
MKNK2 Q9HBH9 5/20 0.41
GPR119 Q8TDV5 1/20 0.41
KDR P35968 1/20 0.41
ABL1 P00519 1/20 0.41
OPRM1 P35372 1/20 0.41
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
NR4A2 P43354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5229005 0.85 CYP19A1 (0.60) KMOCYP11B1CYP11B2CYP19A1SLC2A1
SCHEMBL3497193 0.80 KDR (0.44) KMOCYP11B1CYP11B2CYP19A1MKNK1
SCHEMBL5226019 0.79 KMO (0.67) KMOCYP11B1CYP11B2CYP19A1MKNK1
SCHEMBL29350345 0.76 ALDH1A1 (0.66) CYP11B1CYP11B2ALDH1A1CYP1A2CYP2C9
SCHEMBL3654895 0.76 ALDH1A1 (0.66) CYP11B1CYP11B2ALDH1A1CYP1A2CYP2C9
Trifluoroacetic Acid SCHEMBL3497192 0.75 KMO (0.57) PDK2KMOCYP11B1CYP11B2MKNK1
SCHEMBL20354394 0.75 AURKA (0.47) PDK2KMOCYP11B1CYP11B2CYP19A1
SCHEMBL7595533 0.75 NOTUM (0.47) CYP1A2CYP2C19
SCHEMBL3070779 0.75 NOTUM (0.47) CYP1A2CYP2C19
SCHEMBL1422877 0.75 NPC1 (0.56) ALDH1A1CYP1A2CYP2C9CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC PDK2 668/4885KMO 3580/4885CYP11B1 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.